Ninety-three percent repeat business and 15% revenue growth in a single year puts PSI CRO in an unusual position for a mid-size CRO: sponsors keep coming back, which suggests the agility argument it plans to make at OCT New England next week is grounded in something operational rather than just a conference pitch.
On October 27 at Encore Boston Harbor in Boston, Benjamin Raccanova, PSI’s Head of Business Oversight, joins Stream C of the 18th Annual Outsourcing in Clinical Trials New England conference for a peer-driven session on how small and emerging biotech sponsors can hold onto operational control while scaling global programs. The pressure point is real: investor timelines, regulatory scrutiny, and the site-level complexity introduced by the FDA’s 2024 final guidance on decentralized clinical trials all pull in different directions for a sponsor that doesn’t have a 500-person clinical operations team to absorb the friction.
The debate framing matters here. Raccanova’s panel asks directly whether large CRO operating models are equipped to serve emerging biotech, which sets up a structural question that PSI has a commercial interest in answering a particular way, but also has data to back up. In 2024, 93% of PSI’s studies enrolled on time or ahead of schedule. For a biotech sponsor burning cash against a runway, a slip in enrollment doesn’t just delay a readout, it often triggers a bridge financing conversation.
The session runs at 3:15 PM on October 27. Whether the peer discussion produces anything transferable beyond the room will depend on how many attending sponsors are willing to describe what broke in their last CRO relationship out loud. That candor, not the panel format itself, is what tends to make these conversations useful.
Source link: https://psi-cro.com/agile-cro-models-emerging-biotech-oct-new-england-2026/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
